Last reviewed · How we verify

Millet Roux — Portfolio Competitive Intelligence Brief

Millet Roux pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Valeriana officinalis Valeriana officinalis marketed Standardized Chemical Allergen [EPC]
Passiflora Passiflora marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Deseret Biologicals, Inc. · 1 shared drug class
  3. Donat R. Spahn · 1 shared drug class
  4. Dr. Laurence Klotz · 1 shared drug class
  5. Marjan Industria e Comercio ltda · 1 shared drug class
  6. Nantes University Hospital · 1 shared drug class
  7. Nutritional Specialties, Inc. · 1 shared drug class
  8. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Millet Roux:

Cite this brief

Drug Landscape (2026). Millet Roux — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/millet-roux. Accessed 2026-06-09.

Related